IRVINE, Calif., Aug. 23, 2005 (PRIMEZONE) -- "The recent ruling against Merck (NYSE:MRK) further amplifies the biotechnology and pharmaceutical industry's insatiable appetite for new products," stated SmallCap Sentinel analyst, D.R. Clark. "Losing Vioxx as a profit superstar in their portfolio of offerings is an enormous loss as will be any potential punitive damages awarded to plaintiffs. This singular event paired with the pending horde of aging, drug-consuming Baby Boomers begins to explain why some emergent biotechnology and pharmaceutical technology companies are receiving healthy investment dollars of late. The demand is obvious."
MIV Therapeutics, Inc. (OTCBB:MIVT), a developer of next-generation biocompatible stent coatings and drug delivery technologies for cardiovascular stents and for a broad range of implantable medical devices, announced Monday that the company had received a $4.14 million equity financing to accelerate research efforts.
An informational report "Innovations in Biotechnology" is available free of charge at www.SmallCapSentinel.com
The report will address issues regarding emergent biotechnology potentially affecting companies such as Johnson and Johnson (NYSE:JNJ), Pfizer Inc. (NYSE:PFE), and the aforementioned.
Interested parties may view additional information about MIVT via this direct link: http://www.trilogy-capital.com/tcp/mivt/factsheet.html
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that will affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid fifteen hundred dollars by MIV Therapeutics Corp. for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.